Home › Funds › MPM BioImpact LLC › URGN

MPM BioImpact LLC position in URGN

UROGEN PHARMA LTD · Health Care

MPM BioImpact LLC reported holding 933,415 shares of URGN (UROGEN PHARMA LTD) in its Q2 2026 13F filing — a position valued at US$34.3M, representing 2.09% of its reported portfolio and ranking #18 among its reported holdings. MPM BioImpact LLC has disclosed URGN holdings in 4 of the last 4 reported quarters, going back to Q3 2025.

Latest position (Q2 2026)933.41K sh
Reported value held$34.35M
Portfolio Weight2.09%
First reportedQ3 2025
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How MPM BioImpact LLC's URGN position evolved

MPM BioImpact LLC first disclosed a stake in URGN in Q3 2025 at 135,000 shares (US$2.7M). The position peaked in Q2 2026 at 933,415 shares, worth US$34.3M. Across 4 filings, MPM BioImpact LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 933,415 shares valued at US$34.3M — a reduction of -10,388 shares quarter over quarter.. Notable position changes include a 597% increase in Q4 2025 (shares fell 23% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2025 135.00K $2.69M New
Q4 2025 941.38K $22.05M Add
Q1 2026 943.80K $16.97M Hold
Q2 2026 933.41K $34.35M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About URGN and 13F data

URGN (UROGEN PHARMA LTD) is a Health Care company. 39 other funds we track also report a position in URGN — the largest reported positions include RTW INVESTMENTS, LP (US$167.2M), Kynam Capital Management, LP (US$89.6M), Jefferies Financial Group Inc. (US$80.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding URGN

All URGN fund holders →

FAQ

How long has MPM BioImpact LLC held URGN?

MPM BioImpact LLC has disclosed URGN holdings in 4 of the last 4 reported quarters, going back to Q3 2025.

What is MPM BioImpact LLC's current position in URGN?

As of Q2 2026, MPM BioImpact LLC holds 933.41K shares of URGN (UROGEN PHARMA LTD), valued at $34.35M, representing 2.09% of its reported portfolio and ranking #18.

Has MPM BioImpact LLC been buying or selling URGN?

In the latest 13F filing (Q2 2026), MPM BioImpact LLC reduced its position in URGN. The position peaked in Q2 2026 at 933.41K shares.

Which other funds hold URGN?

Other major institutional holders of URGN include RTW INVESTMENTS, LP, Kynam Capital Management, LP, Jefferies Financial Group Inc., among 39 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.